×
S&P 500   3,816.89 (-0.12%)
DOW   30,999.34 (+0.17%)
QQQ   283.55 (+0.00%)
AAPL   139.77 (+1.70%)
MSFT   261.08 (+1.79%)
META   162.90 (+1.38%)
GOOGL   2,238.53 (-0.07%)
AMZN   109.30 (+1.77%)
TSLA   671.81 (-3.75%)
NVDA   154.56 (-3.29%)
NIO   21.40 (-4.29%)
BABA   115.28 (-1.27%)
AMD   77.32 (-4.28%)
MU   55.93 (-3.34%)
CGC   3.50 (-3.05%)
T   20.70 (+0.44%)
GE   63.89 (-3.02%)
F   11.49 (-2.71%)
DIS   94.80 (-1.17%)
AMC   13.24 (-1.05%)
PFE   51.02 (+0.71%)
PYPL   71.32 (-0.70%)
NFLX   176.62 (-1.66%)
S&P 500   3,816.89 (-0.12%)
DOW   30,999.34 (+0.17%)
QQQ   283.55 (+0.00%)
AAPL   139.77 (+1.70%)
MSFT   261.08 (+1.79%)
META   162.90 (+1.38%)
GOOGL   2,238.53 (-0.07%)
AMZN   109.30 (+1.77%)
TSLA   671.81 (-3.75%)
NVDA   154.56 (-3.29%)
NIO   21.40 (-4.29%)
BABA   115.28 (-1.27%)
AMD   77.32 (-4.28%)
MU   55.93 (-3.34%)
CGC   3.50 (-3.05%)
T   20.70 (+0.44%)
GE   63.89 (-3.02%)
F   11.49 (-2.71%)
DIS   94.80 (-1.17%)
AMC   13.24 (-1.05%)
PFE   51.02 (+0.71%)
PYPL   71.32 (-0.70%)
NFLX   176.62 (-1.66%)
S&P 500   3,816.89 (-0.12%)
DOW   30,999.34 (+0.17%)
QQQ   283.55 (+0.00%)
AAPL   139.77 (+1.70%)
MSFT   261.08 (+1.79%)
META   162.90 (+1.38%)
GOOGL   2,238.53 (-0.07%)
AMZN   109.30 (+1.77%)
TSLA   671.81 (-3.75%)
NVDA   154.56 (-3.29%)
NIO   21.40 (-4.29%)
BABA   115.28 (-1.27%)
AMD   77.32 (-4.28%)
MU   55.93 (-3.34%)
CGC   3.50 (-3.05%)
T   20.70 (+0.44%)
GE   63.89 (-3.02%)
F   11.49 (-2.71%)
DIS   94.80 (-1.17%)
AMC   13.24 (-1.05%)
PFE   51.02 (+0.71%)
PYPL   71.32 (-0.70%)
NFLX   176.62 (-1.66%)
S&P 500   3,816.89 (-0.12%)
DOW   30,999.34 (+0.17%)
QQQ   283.55 (+0.00%)
AAPL   139.77 (+1.70%)
MSFT   261.08 (+1.79%)
META   162.90 (+1.38%)
GOOGL   2,238.53 (-0.07%)
AMZN   109.30 (+1.77%)
TSLA   671.81 (-3.75%)
NVDA   154.56 (-3.29%)
NIO   21.40 (-4.29%)
BABA   115.28 (-1.27%)
AMD   77.32 (-4.28%)
MU   55.93 (-3.34%)
CGC   3.50 (-3.05%)
T   20.70 (+0.44%)
GE   63.89 (-3.02%)
F   11.49 (-2.71%)
DIS   94.80 (-1.17%)
AMC   13.24 (-1.05%)
PFE   51.02 (+0.71%)
PYPL   71.32 (-0.70%)
NFLX   176.62 (-1.66%)
NASDAQ:XERS

Xeris Biopharma Stock Forecast, Price & News

$1.40
-0.11 (-6.95%)
(As of 06/29/2022 11:25 AM ET)
Add
Compare
Today's Range
$1.40
$1.52
50-Day Range
$1.51
$2.46
52-Week Range
$1.25
$4.59
Volume
33,330 shs
Average Volume
2.08 million shs
Market Capitalization
$93.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.13
30 days | 90 days | 365 days | Advanced Chart

Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock Forecast (MarketRank)

Overall MarketRank

2.06 out of 5 stars

Medical Sector

535th out of 1,433 stocks

Pharmaceutical Preparations Industry

230th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Xeris Biopharma logo

About Xeris Biopharma (NASDAQ:XERS)

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

XERS Stock News Headlines

Xeris Biopharma spikes as CEO buys company shares
10 Stocks I'm Watching in 2022: An Update
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XERS
Fax
N/A
Employees
294
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
6/29/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.13
High Stock Price Forecast
$6.50
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+335.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-122.72 million
Net Margins
-217.81%
Pretax Margin
-218.45%

Debt

Sales & Book Value

Annual Sales
$49.59 million
Book Value
$1.43 per share

Miscellaneous

Free Float
63,830,000
Market Cap
$93.43 million
Optionable
Not Optionable
Beta
N/A














Xeris Biopharma Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xeris Biopharma stock.
View analyst ratings for Xeris Biopharma
or view top-rated stocks.

What is Xeris Biopharma's stock price forecast for 2022?

4 brokerages have issued twelve-month target prices for Xeris Biopharma's shares. Their XERS stock forecasts range from $6.00 to $6.50. On average, they predict Xeris Biopharma's share price to reach $6.13 in the next year. This suggests a possible upside of 335.9% from the stock's current price.
View analysts' price targets for Xeris Biopharma
or view top-rated stocks among Wall Street analysts.

How has Xeris Biopharma's stock price performed in 2022?

Xeris Biopharma's stock was trading at $2.93 at the beginning of 2022. Since then, XERS shares have decreased by 52.0% and is now trading at $1.4050.
View the best growth stocks for 2022 here
.

When is Xeris Biopharma's next earnings date?

Xeris Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Xeris Biopharma
.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The business earned $22.07 million during the quarter, compared to the consensus estimate of $22.92 million. Xeris Biopharma had a negative net margin of 217.81% and a negative trailing twelve-month return on equity of 258.57%.
View Xeris Biopharma's earnings history
.

Who are Xeris Biopharma's key executives?

Xeris Biopharma's management team includes the following people:
  • Mr. Paul R. Edick, Chairman & CEO (Age 66, Pay $1.27M) (LinkedIn Profile)
  • Mr. John P. Shannon, Pres & COO (Age 60, Pay $966.64k)
  • Ms. Beth P. Hecht J.D., Chief Legal Officer & Corp. Sec. (Age 58, Pay $662.99k)
  • Dr. Steven J. Prestrelski MBA, Ph.D., Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Steven M. Pieper, Chief Financial Officer (Age 45)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
  • Dr. Kenneth E. Johnson Pharm. D., Pharm.D., Sr. VP of Global Devel. & Medical Affairs (Age 59)
  • Mr. Kevin McCulloch, Sr. VP of Global Operations & Bus. Devel.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

When did Xeris Biopharma IPO?

(XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Biopharma's stock symbol?

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.83%), BlackRock Inc. (3.00%), Goldman Sachs Group Inc. (1.09%), Renaissance Technologies LLC (1.04%), Granahan Investment Management LLC (0.61%) and State Street Corp (0.58%). Company insiders that own Xeris Biopharma stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends for Xeris Biopharma
.

Which major investors are selling Xeris Biopharma stock?

XERS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deltec Asset Management LLC, Simplex Trading LLC, Granahan Investment Management LLC, Brown Advisory Inc., Commonwealth Equity Services LLC, Dimensional Fund Advisors LP, and Qube Research & Technologies Ltd.
View insider buying and selling activity for Xeris Biopharma
or view top insider-selling stocks.

Which major investors are buying Xeris Biopharma stock?

XERS stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Citigroup Inc., BlackRock Inc., Yakira Capital Management Inc., Vanguard Group Inc., Virtu Financial LLC, UBS Group AG, and Sciencast Management LP.
View insider buying and selling activity for Xeris Biopharma
or or view top insider-buying stocks.

How do I buy shares of Xeris Biopharma?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Biopharma's stock price today?

One share of XERS stock can currently be purchased for approximately $1.41.

How much money does Xeris Biopharma make?

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $93.43 million and generates $49.59 million in revenue each year. The company earns $-122.72 million in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Xeris Biopharma have?

Xeris Biopharma employs 294 workers across the globe.

How can I contact Xeris Biopharma?

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for Xeris Biopharma is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at [email protected].

This page (NASDAQ:XERS) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.